[e-drug] NEJM this week: Clinical trials ethics (cont'd)

[Peter Lurie <PLURIE@citizen.org>]

E-drug: NEJM this week: Clinical trials ethics (cont'd)
-------------------------------------------------------------------------

If some patients are intolerant to ACE inhibitors, the investigator
has two ethical options:

a. conduct a placebo-controlled trial only in ACE inhibitor-intolerant
patients (see, eg, Granger, et al Am Heart J 2000;139(4):609-617)
  OR
b. conduct an active-controlled trial, allowing cross-over from the
ACE inhibitor group separately, providing very useful clinical
information.

If 4% of ACE inhibitor-receiving patients develop cough, this is no
justification for 96% of patients in a comparison arm to receive
placebo.

Peter Lurie, MD, MPH
Deputy Director
Public Citizen's Health Research Group
1600 20th Street, NW
Washington, DC 20009
Phone: (202)588-7781
Fax: (202)588-7796
Email: plurie@citizen.org
Web address: http://www.citizen.org


--
Send mail for the `E-Drug' conference to `e-drug@usa.healthnet.org'.
Information and archive http://satellife.healthnet.org/programs/edrug.html
Mail administrative requests to `majordomo@usa.healthnet.org'.
For additional assistance, send mail to:  `owner-e-drug@usa.healthnet.org'.